erythromycin has been researched along with gemifloxacin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dubois, J; St-Pierre, C | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD | 1 |
1 review(s) available for erythromycin and gemifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for erythromycin and gemifloxacin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin | 2010 |
Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Microbial Sensitivity Tests; Naphthyridines | 2000 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Biological Transport; Cell Line; Cell Membrane Permeability; Dogs; Dose-Response Relationship, Drug; Erythromycin; Fluoresceins; Fluoroquinolones; Gemifloxacin; Gene Expression Regulation; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Naphthyridines; Pregnane X Receptor; Real-Time Polymerase Chain Reaction; Receptors, Steroid; RNA, Messenger; Time Factors; Transfection | 2011 |